Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 7:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–41 of 17 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Myxoid Liposarcoma Clear all
Not listed Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Ewing Sarcoma, Myxoid Liposarcoma, Desmoplastic Small Round Cell Tumor, Extraskeletal Myxoid Chondrosarcoma, Angiomatoid Fibrous Histiocytoma, Clear Cell Sarcoma, Myoepithelial Tumor, Low Grade Fibromyxoid Sarcoma, Sclerosing Epithelioid Fibrosarcoma
Interventions
Seclidemstat
Drug
Lead sponsor
Salarius Pharmaceuticals, LLC
Industry
Eligibility
12 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Jul 31, 2023 · Synced May 21, 2026, 7:40 PM EDT
Terminated Phase 1 Interventional Results available
View directory record Official record
Conditions
Neoplasms
Interventions
GSK3845097, Cyclophosphamide, Fludarabine
Drug
Lead sponsor
Adaptimmune
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
12
States / cities
New Haven, Connecticut • Jacksonville, Florida • Tampa, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2024 · Synced May 21, 2026, 7:40 PM EDT
Active, not recruiting Phase 2 Interventional Results available
View directory record Official record
Conditions
Synovial Sarcoma, Myxoid Liposarcoma
Interventions
afamitresgene autoleucel (previously ADP-A2M4)
Genetic
Lead sponsor
USWM CT, LLC
Industry
Eligibility
10 Years to 75 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2038
U.S. locations
17
States / cities
Duarte, California • Palo Alto, California • Aurora, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced May 21, 2026, 7:40 PM EDT
Not listed Phase 2 Interventional
View directory record Official record
Conditions
Myxoid Liposarcoma
Interventions
Brostallicin
Drug
Lead sponsor
Systems Medicine LLC
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Feb 25, 2010 · Synced May 21, 2026, 7:40 PM EDT
Withdrawn Phase 1 Interventional
View directory record Official record
Conditions
Adult Synovial Sarcoma, Myxoid/Round Cell Liposarcoma, Recurrent Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma
Interventions
Autologous NY-ESO-1-specific CD8-positive T Lymphocytes, Cyclophosphamide, Laboratory Biomarker Analysis
Biological · Drug · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 2, 2016 · Synced May 21, 2026, 7:40 PM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Synovial Sarcoma, Myxoid/Round Cell Liposarcoma
Interventions
Fludarabine phosphate, NY-ESO-1 TCR/IL-15 NK, Cyclophosphamide
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
16 Years to 80 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced May 21, 2026, 7:40 PM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Metastatic Leiomyosarcoma, Metastatic Synovial Sarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Advanced Myxoid Liposarcoma, Advanced Soft Tissue Sarcoma, Metastatic Myxoid Liposarcoma, Metastatic Round Cell Liposarcoma, Metastatic Soft Tissue Sarcoma, Refractory Leiomyosarcoma, Refractory Myxoid Liposarcoma, Refractory Round Cell Liposarcoma, Refractory Soft Tissue Sarcoma, Refractory Synovial Sarcoma, Refractory Undifferentiated Pleomorphic Sarcoma, Advanced Leiomyosarcoma, Advanced Synovial Sarcoma, Advanced Undifferentiated Pleomorphic Sarcoma, Metastatic Chondrosarcoma
Interventions
Itacitinib, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced May 21, 2026, 7:40 PM EDT
Recruiting Early Phase 1 Interventional
View directory record Official record
Conditions
Myxoid Liposarcoma, Round Cell Liposarcoma, Synovial Sarcoma
Interventions
Biospecimen Collection, Computed Tomography, Leukapheresis, Magnetic Resonance Imaging, Nogapendekin Alfa Inbakicept, X-Ray Imaging
Procedure · Biological
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 80 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced May 21, 2026, 7:40 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Liposarcoma,Myxoid
Interventions
Trabectedin, Dexamethasone
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
4
States / cities
Coeur d'Alene, Idaho • Park Ridge, Illinois • Iowa City, Iowa + 1 more
Source: ClinicalTrials.gov public record
Updated May 6, 2014 · Synced May 21, 2026, 7:40 PM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Multiple Myeloma, Melanoma, Synovial Sarcoma, Myxoid/Round Cell Liposarcoma
Interventions
NY-ESO-1 redirected autologous T cells with CRISPR edited endogenous TCR and PD-1, Cyclophosphamide, Fludarabine, NY-ESO-1 expression testing
Biological · Drug · Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced May 21, 2026, 7:40 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Metastatic Myxoid Liposarcoma, Metastatic Round Cell Liposarcoma, Metastatic Synovial Sarcoma, Recurrent Mycosis Fungoides and Sezary Syndrome, Refractory Mycosis Fungoides and Sezary Syndrome, Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage II Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage III Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IIIA Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IIIB Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IVA Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IVB Mycosis Fungoides and Sezary Syndrome AJCC v7, Unresectable Synovial Sarcoma
Interventions
Interferon Gamma-1b, Laboratory Biomarker Analysis, Pembrolizumab
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
7
States / cities
Palo Alto, California • Miami, Florida • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2023 · Synced May 21, 2026, 7:40 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Adult Alveolar Soft Part Sarcoma, Adult Angiosarcoma, Adult Desmoplastic Small Round Cell Tumor, Adult Epithelioid Hemangioendothelioma, Adult Epithelioid Sarcoma, Adult Extraskeletal Myxoid Chondrosarcoma, Adult Extraskeletal Osteosarcoma, Adult Fibrosarcoma, Adult Leiomyosarcoma, Adult Liposarcoma, Adult Malignant Peripheral Nerve Sheath Tumor, Adult Rhabdomyosarcoma, Adult Synovial Sarcoma, Adult Undifferentiated Pleomorphic Sarcoma, Malignant Adult Hemangiopericytoma, Recurrent Adult Soft Tissue Sarcoma, Sarcoma, Stage III Adult Soft Tissue Sarcoma AJCC v7, Stage IV Adult Soft Tissue Sarcoma AJCC v7
Interventions
Gemcitabine, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Pazopanib, Pazopanib Hydrochloride, Placebo Administration
Drug · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
2
States / cities
Portland, Oregon • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 26, 2021 · Synced May 21, 2026, 7:40 PM EDT
Not listed Phase 2 Interventional
View directory record Official record
Conditions
Endometrial Cancer, Ovarian Cancer, Sarcoma
Interventions
temozolomide
Drug
Lead sponsor
Herbert Irving Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 5, 2014 · Synced May 21, 2026, 7:40 PM EDT
Completed Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Adult Alveolar Soft Part Sarcoma, Adult Angiosarcoma, Adult Desmoplastic Small Round Cell Tumor, Adult Epithelioid Hemangioendothelioma, Adult Epithelioid Sarcoma, Adult Extraskeletal Myxoid Chondrosarcoma, Adult Extraskeletal Osteosarcoma, Adult Fibrosarcoma, Adult Leiomyosarcoma, Adult Liposarcoma, Adult Malignant Mesenchymoma, Adult Malignant Peripheral Nerve Sheath Tumor, Adult Rhabdomyosarcoma, Adult Synovial Sarcoma, Adult Unclassified Pleomorphic Sarcoma, Chondrosarcoma, Clear Cell Sarcoma of the Kidney, Conjunctival Kaposi Sarcoma, Dermatofibrosarcoma Protuberans, Gastrointestinal Stromal Tumor, Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Metastatic Osteosarcoma, Ovarian Sarcoma, Recurrent Adult Soft Tissue Sarcoma, Recurrent Adult Unclassified Pleomorphic Sarcoma of Bone, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Kaposi Sarcoma, Recurrent Osteosarcoma, Recurrent Uterine Corpus Sarcoma, Small Intestine Leiomyosarcoma, Stage III Adult Soft Tissue Sarcoma, Stage III Uterine Sarcoma, Stage IV Adult Soft Tissue Sarcoma, Stage IV Uterine Sarcoma, Unclassified Pleomorphic Sarcoma of Bone
Interventions
Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis, Pharmacological Study, Vismodegib
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 14, 2018 · Synced May 21, 2026, 7:40 PM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Adipocytic Neoplasm, Liposarcoma, Atypical Fibroxanthoma, Angiomatoid Fibrous Histiocytoma, Myoepithelioma, Fibrosarcoma NOS, Myxofibrosarcoma, Angiosarcoma, Osteosarcoma, Extraskeletal
Interventions
Surgical resection, Proton beam radiation therapy, Pazopanib, Ifosfamide, Doxorubicin, Selinexor
Procedure · Radiation · Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 30 Years
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2037
U.S. locations
6
States / cities
Chicago, Illinois • Baton Rouge, Louisiana • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced May 21, 2026, 7:40 PM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Neoplasms
Interventions
Letetresgene autoleucel (lete-cel, GSK3377794), Fludarabine, Cyclophosphamide
Drug
Lead sponsor
USWM CT, LLC
Industry
Eligibility
10 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
24
States / cities
Duarte, California • Stanford, California • Denver, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced May 21, 2026, 7:40 PM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Well Differentiated Liposarcoma, Dedifferentiated Liposarcoma, Liposarcoma, Myxoid Liposarcoma, Round Cell Liposarcoma, Myxoid Pleomorphic Liposarcoma, Pleomorphic Liposarcoma, Unresectable Liposarcoma, Unresectable Dedifferentiated Liposarcoma
Interventions
Mirdametinib, Palbociclib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced May 21, 2026, 7:40 PM EDT